The estimated Net Worth of Louis O'dea is at least $1.16 Million dollars as of 23 March 2020. Louis dea owns over 3,198 units of Akcea Therapeutics Inc stock worth over $1,119,308 and over the last 7 years Louis sold AKCA stock worth over $37,577.
Sign up
Louis dea AKCA stock SEC Form 4 insiders trading
Louis has made over 1 trades of the Akcea Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Louis sold 3,198 units of AKCA stock worth $37,577 on 23 March 2020.
The largest trade Louis's ever made was selling 3,198 units of Akcea Therapeutics Inc stock on 23 March 2020 worth over $37,577. On average, Louis trades about 457 units every 0 days since 2018. As of 23 March 2020 Louis still owns at least 61,602 units of Akcea Therapeutics Inc stock.
You can see the complete history of Louis dea stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Louis dea's mailing address?
Louis's mailing address filed with the SEC is C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON, MA, 02210.
Insiders trading at Akcea Therapeutics Inc
Over the last 7 years, insiders at Akcea Therapeutics Inc have traded over $384,023 worth of Akcea Therapeutics Inc stock and bought 35,029,381 units worth $610,464,515 . The most active insiders traders include Pharmaceuticals Inc Ionis, Paula Soteropoulos und B Lynne Parshall. On average, Akcea Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $40,228,816. The most recent stock trade was executed by Pharmaceuticals Inc Ionis on 10 October 2020, trading 21,237,715 units of AKCA stock currently worth $385,464,527.
What does Akcea Therapeutics Inc's logo look like?
Complete history of Louis dea stock trades at Akcea Therapeutics Inc
Akcea Therapeutics Inc executives and stock owners
Akcea Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barbara Yanni,
Director -
Amber Salzman,
Director -
Joseph Iii Klein,
Director -
Michael J. Yang,
Director -
Pharmaceuticals Inc Ionis,
10% owner -
Michael F Mac Lean,
Chief Financial Officer -
Jeff Marc Goldberg,
Chief Operating Officer -
Louis O'dea,
Chief Medical Officer -
Paula Soteropoulos,
Chief Executive Officer -
Elaine Hochberg,
Director -
Edward M Fitzgerald,
Director -
Sandford D Smith,
Director -
Richard A Moscicki,
Director -
Sarah Boyce,
President -
Christopher Gabrieli,
Director -
Alex G. Howarth,
Chief Operating Officer -
B Lynne Parshall,
Director -
Kyle Jenne,
Chief Commercial Officer -
Michael Dennis Price,
Chief Financial Officer -
Damien Mc Devitt,
Chief Executive Officer -
Joshua F. Patterson,
General Counsel -
William T. Andrews,
Chief Medical Officer